ICH Q9 Quality risk management - Scientific guideline
Table of contents
This document provides principles and examples of tools for quality risk management that can be applied to different aspects of pharmaceutical quality. These aspects include development, manufacturing, distribution, and the inspection and submission/review processes throughout the lifecycle of drug substances, drug products, biological and biotechnological products.
Keywords: Risk assessment, quality risk management, risk, harm, hazard, failure mode and effects analysis (FMEA)
-
List item
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q9 (R1) on quality risk management - Step 5 - Revision 1 (PDF/444.91 KB)
Adopted
First published: 06/02/2023
Legal effective date: 26/07/2023
EMA/CHMP/ICH/24235/2006 -
List item
Draft International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q9 (R1) on quality risk management - Step 2b (PDF/706.71 KB)
Draft: consultation closed
First published: 16/12/2021
Consultation dates: 16/12/2021 to 15/03/2022
EMA/CHMP/ICH/24235/2006 -
List item
Overview of comments received on ICH guideline Q9 (R1) on quality risk management (EMA/CHMP/ICH/24235/2006) (PDF/420.33 KB)
First published: 20/04/2022
EMA/158487/2022 -
List item
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline Q9 on quality risk management - Step 5 - First version (PDF/330.64 KB)
Adopted
First published: 19/01/2006
Last updated: 28/05/2014
EMA/CHMP/ICH/24235/2006